Crown Reserve Acquisition Corp. I

What they do

Crown Reserve is a Cayman Islands exempted company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It has no principal operations and generates no operating revenues. Its only activities since inception have been organizational, IPO preparation, and identifying a target, including the Business Combination Agreement with Carvix signed on March 30, 2026.

Revenue drivers

• Trust Account dividends — Non-operating income from dividends earned on marketable securities held in the Trust Account. For the six months ended June 30, 2026, dividends were $3,073,108.
• No operating revenues — The company has not generated any operating revenues to date and will not do so until a Business Combination is completed.

Recent performance

For the three months ended June 30, 2026, net income was $1,353,765, consisting of $1,548,367 in Trust Account dividends, offset by general and administrative costs of $53,125, professional fees of $25,000, and a $116,477 loss on change in fair value of warrant liability. For the six months ended June 30, 2026, net income was $1,090,272, with dividends of $3,073,108 offset by general and administrative costs of $121,962, professional fees of $140,000, and a $1,720,874 loss on warrant liability changes. The Trust Account held $173,403,838 as of December 31, 2025, including $903,838 in dividends. Total assets were $176.6M as of June 30, 2026, with shareholder equity of negative $3.4M. Cash and equivalents were $25,149 as of September 30, 2025.

Strategy

Management intends to effectuate its initial Business Combination using cash from the Trust Account, its shares, debt, or a combination. The company entered into a Business Combination Agreement with Carvix on March 30, 2026, which will involve a domestication to Delaware and a merger of Merger Sub with Carvix, with Carvix surviving as a wholly owned subsidiary. The company expects to incur significant costs in pursuing the Business Combination. There is no assurance that the planned Business Combination will be successful.

Risks

• Failure to complete Business Combination — If the company does not complete a Business Combination within the Combination Period, which ends November 10, 2026 (automatically extended to February 10, 2027 upon signing a definitive agreement), shareholders may redeem their Public Shares and the company may liquidate.
• No operating history — The company has no operating results and has never generated operating revenues, providing no basis for investors to evaluate its ability to achieve its business objective.
• Target acquisition risk — The company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the Trust Account value, and there is no guarantee that any deal will meet this requirement or be completed.
• Warrant liability volatility — Changes in the fair value of warrant liabilities have caused losses and could continue to affect reported net income and shareholder equity, which was negative as of June 30, 2026.

Outlook

Management expects to continue incurring significant costs in pursuing its Business Combination plans. The Outside Date for consummating the Carvix transaction is September 30, 2026. The company cannot assure that its plans to complete a Business Combination will be successful.